USANA Health Sciences, Inc. (NYSE:USNA), is not the largest company out there, but it received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$104 at one point, and dropping to the lows of US$92.32. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether USANA Health Sciences' current trading price of US$94.30 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let’s take a look at USANA Health Sciences’s outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

See our latest analysis for USANA Health Sciences

What is USANA Health Sciences worth?

According to my valuation model, USANA Health Sciences seems to be fairly priced at around 9.0% below my intrinsic value, which means if you buy USANA Health Sciences today, you’d be paying a reasonable price for it. And if you believe that the stock is really worth $103.62, then there isn’t much room for the share price grow beyond what it’s currently trading. In addition to this, USANA Health Sciences has a low beta, which suggests its share price is less volatile than the wider market.

What does the future of USANA Health Sciences look like? earnings-and-revenue-growth

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at the company's future expectations. However, with a negative profit growth of -15% expected over the next couple of years, near-term growth certainly doesn’t appear to be a driver for a buy decision for USANA Health Sciences. This certainty tips the risk-return scale towards higher risk.



What this means for you:

Are you a shareholder? Currently, USNA appears to be trading around its fair value, but given the uncertainty from negative returns in the future, this could be the right time to reduce the risk in your portfolio. Is your current exposure to the stock beneficial for your total portfolio? And is the opportunity cost of holding a negative-outlook stock too high? Before you make a decision on the stock, take a look at whether its fundamentals have changed.

Are you a potential investor? If you’ve been keeping tabs on USNA for a while, now may not be the most optimal time to buy, given it is trading around its fair value. The stock appears to be trading at fair value, which means there’s less benefit from mispricing. Furthermore, the negative growth outlook increases the risk of holding the stock. However, there are also other important factors we haven’t considered today, which can help gel your views on USNA should the price fluctuate below its true value.

If you'd like to know more about USANA Health Sciences as a business, it's important to be aware of any risks it's facing. To that end, you should learn about the 2 warning signs we've spotted with USANA Health Sciences (including 1 which makes us a bit uncomfortable).

If you are no longer interested in USANA Health Sciences, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.